Summary of Key Points Core Viewpoint - 医渡科技 has been actively repurchasing its shares, indicating confidence in its market position and future prospects [1] Group 1: Share Buyback Activity - On October 17, 医渡科技 spent HKD 1.013 million to repurchase 181,000 shares [1] - This week, the company has conducted three buybacks totaling approximately 2.685 million shares, with a total expenditure exceeding HKD 15.6 million [1] - Since September 26, the company has executed five buybacks, amounting to around 3.373 million shares and nearly HKD 20 million in total [1] Group 2: Southbound Capital Inflows - On October 14, southbound funds net purchased HKD 34.7273 million worth of 医渡科技 shares, marking the highest net inflow since September 1, 2025 [1] - The net buying has continued for three consecutive days, with a cumulative net purchase of HKD 57.79 million [1] Group 3: Product Development and Market Support - Recently, the world's first topical treatment for proliferative superficial infantile hemangioma, Timolol Maleate Gel, has been approved for market release [1] - 医渡科技 provided critical market research and project analysis services that supported the drug's development and market entry [1]
医渡科技周内3次回购超1560万港元 南向资金连续加仓